Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability
- PMID: 23314530
- DOI: 10.1515/dmdi-2012-0033
Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability
Abstract
Background: Acute muscle injury and potentially fatal rhabdomyolysis may occur with use of statins and certain interacting medications. This investigation assessed risk for myopathy in patients receiving treatment with a statin in combination with daptomycin, a medication also associated with muscle injury.
Methods: Patients hospitalized from July 1, 2005, through June 30, 2010, who received simvastatin or rosuvastatin concurrently with daptomycin were identified and their medical records were examined. Patients were judged to have treatment-related muscle injury if their records contained evidence of myalgia with or without weakness and secondarily impaired mobility together with elevated creatine kinase (CK) levels. These assessments were compared with similar data from hospitalized patients who received a statin alone.
Results: A total of 52 patients received 66 courses of concurrent treatment with simvastatin or rosuvastatin and daptomycin. Of these, no patient (0%) met evidentiary requirements for diagnosis of myopathy or related complications. No patient (0%) developed muscle pain or discomfort and none developed markedly elevated CK levels. The incidence of asymptomatic elevations of CK in these simvastatin or rosuvastatin plus daptomycin recipients (9%) was statistically indistinguishable from the incidence of CK elevations found in a cohort of 105 inpatients who received simvastatin or rosuvastatin alone (21%; p=0.135).
Conclusions: In patients receiving treatment with simvastatin or rosuvastatin and daptomycin, no symptoms or objective evidence of muscle injury attributable to a drug interaction were identified. These findings are consistent with data indicating that the myopathic effects of statins and daptomycin are incited by disparate and perhaps unique pharmacological mechanisms. Risk of muscle injury therefore appears to be no greater when a statin is administered with daptomycin than when either medication is used alone.
Similar articles
-
Safety of rosuvastatin.Am J Cardiol. 2004 Oct 1;94(7):882-8. doi: 10.1016/j.amjcard.2004.06.049. Am J Cardiol. 2004. PMID: 15464670 Clinical Trial.
-
Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.Clin Ther. 2006 Jun;28(6):933-42. doi: 10.1016/j.clinthera.2006.06.004. Clin Ther. 2006. PMID: 16860175 Clinical Trial.
-
The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases.Pharmacoepidemiol Drug Saf. 2008 Oct;17(10):953-61. doi: 10.1002/pds.1602. Pharmacoepidemiol Drug Saf. 2008. PMID: 18425987
-
Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.Am J Cardiovasc Drugs. 2010;10(1):11-28. doi: 10.2165/13168600-000000000-00000. Am J Cardiovasc Drugs. 2010. PMID: 20104931 Review.
-
Expanding options with a wider range of rosuvastatin doses.Clin Ther. 2006 Nov;28(11):1747-63. doi: 10.1016/j.clinthera.2006.11.004. Clin Ther. 2006. PMID: 17212997 Review.
Cited by
-
Eosinophilic Syndromes Associated With Daptomycin Use: Re-exposure Hypersensitivity Pneumonitis and Prior Peripheral Eosinophilia.Open Forum Infect Dis. 2022 Mar 16;9(4):ofac065. doi: 10.1093/ofid/ofac065. eCollection 2022 Apr. Open Forum Infect Dis. 2022. PMID: 35308486 Free PMC article.
-
Effect of Statin Coadministration on the Risk of Daptomycin-Associated Myopathy.Clin Infect Dis. 2018 Oct 15;67(9):1356-1363. doi: 10.1093/cid/ciy287. Clin Infect Dis. 2018. PMID: 29668884 Free PMC article.
-
Effect of Concomitant 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitor Therapy on Creatine Phosphokinase Levels and Mortality Among Patients Receiving Daptomycin: Retrospective Cohort Study.Infect Dis Ther. 2014 Dec;3(2):225-33. doi: 10.1007/s40121-014-0041-y. Epub 2014 Sep 23. Infect Dis Ther. 2014. PMID: 25245515 Free PMC article.
-
A Retrospective Multisite Case-Control Series of Concomitant Use of Daptomycin and Statins and the Effect on Creatine Phosphokinase.Open Forum Infect Dis. 2019 Nov 7;6(11):ofz444. doi: 10.1093/ofid/ofz444. eCollection 2019 Nov. Open Forum Infect Dis. 2019. PMID: 31723571 Free PMC article.
-
Daptomycin in combination with rosuvastatin induced blood creatine phosphokinase elevation.Eur J Hosp Pharm. 2021 Jul;28(4):234-236. doi: 10.1136/ejhpharm-2020-002218. Epub 2020 Mar 9. Eur J Hosp Pharm. 2021. PMID: 34162676 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous